Company profile: TD2
1.1 - Company Overview
Company description
- Provider of oncology-focused contract research services, offering data-driven clinical study management for Phase I–III trials; preclinical tools with 400+ cancer models to maximize data value and predict patient response; regulatory support (IND readiness, development, filings, FDA interactions); PK/ADME assays; and CDX models including NCI-H1963 (lung) and CCRF-CEM (T-ALL) to accelerate translational oncology.
Products and services
- Clinical Study Management: Engineers the design, planning, and execution of Phase I–III oncology trials using data-driven methods to capture and analyze early signals of response
- Preclinical: Supplies model-rich tools and over 400 cancer models to design and adapt studies that maximize data value and predict patient response for translational oncology research
- Regulatory Support: Manages FDA-engaged regulatory pathways, including IND readiness assessment, program evaluation, IND development and filings, and FDA interactions for oncology therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TD2
Just Evotec Biologics
HQ: United States
Website
- Description: Provider of integrated technologies and services to accelerate biotherapeutics development and reduce manufacturing costs, including continuous manufacturing platforms for antibodies, next-generation biologics and biosimilars within cGMP facilities; a US/EU global network for antibody discovery, cell line, analytical and process development; cGMP biomanufacturing from early clinical to commercial; and partnership opportunities from discovery to market supply.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Just Evotec Biologics company profile →
OmniaBio
HQ: Canada
Website
- Description: Provider of contract development and manufacturing services for gene-modified cell therapies and viral vectors, supporting cell and gene therapy companies from preclinical through commercial scale. Capabilities include automated, closed CAR T and NK process development and manufacturing, lentiviral vector upstream/downstream process optimization, GMP iPSC reprogramming, gene editing and differentiation, cell therapy scale-up, and GMP manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OmniaBio company profile →
S-Cubed
HQ: Denmark
Website
- Description: Provider of consultancy services, including biometrics, biostatistics, data, and visual analytics for pharmaceutical industries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full S-Cubed company profile →
Aptus Clinical
HQ: United Kingdom
Website
- Description: Provider of specialist clinical contract research services, offering Catalyst Oncology, a clinical research organization focusing on oncology supporting biotech companies in developing cancer therapies, and Catalyst Flex, multi-therapeutic functional service provider solutions including clinical operations, data management, biostatistics, programming, safety, and medical writing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aptus Clinical company profile →
Triplan
HQ: Germany
Website
- Description: Provider of general engineering contracting services, offering consulting, site planning, and analysis for the chemical industries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Triplan company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TD2
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TD2
2.2 - Growth funds investing in similar companies to TD2
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TD2
4.2 - Public trading comparable groups for TD2
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →